Amylyx Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Amylyx Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1613% to $380,786,000. The net income raised on $49,271,000 and profit margin reached 13%. Total operating expenses were $316,543,000.
Profit Margin
| 2019 | 1.42M | -14.81M | -1038.99% |
|---|---|---|---|
| 2020 | 650K | -44.83M | -6898% |
| 2021 | 285K | -87.87M | -30834.74% |
| 2022 | 22.23M | -198.37M | -892.38% |
| 2023 | 380.78M | 49.27M | 12.94% |
AMLX Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 380.78M | 22.23M | 285K | 650K | 1.42M |
Cost of revenue | 25.44M | 2.99M | 52K | 24.59M | 11.89M |
Gross profit | 355.34M | 19.23M | 233K | -23.94M | -10.47M |
Operating exp. | |||||
Research and development | 128.18M | 93.45M | 44.04M | 24.59M | 11.89M |
Selling and marketing | 9.5M | 4.4M | 0 | 0 | 0 |
Total operating expenses | 316.54M | 220.57M | 82.68M | 39.00M | 13.55M |
Operating income | 38.80M | -201.34M | -82.68M | -39.00M | -13.55M |
Other income (expenses), net | 15.49M | 3.74M | -5.24M | -3.27M | -162K |
Income before tax | 54.29M | -197.60M | -87.93M | -42.28M | -13.71M |
Income tax expense | 5.02M | 774K | -52K | 2.55M | 1.1M |
Net income | 49.27M | -198.37M | -87.87M | -44.83M | -14.81M |
Earnings per share | |||||
Basic EPS | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
Diluted EPS | 0.7 | -2.98 | -1.52 | -0.79 | -0.26 |
| Data source | Data source | Data source |